ual of Policies and Procedures" (MaPPs) at http://www. fda.gov/cder/mapp.htm under "Pharmacology and Toxicology" is Chapter 7400, the collection of MAPPs that apply to pharmacology and toxicology, mainly management of various CDER Pharmacology/Toxicology Coordinating Committees. Two MaPPs of interest to persons outside of the FDA are 7412.1 Management of CDER Carcinogenicity Assessment Committee (CAC) and Executive CAC, and 7412.2 Distribution of Final Reports from the Carcinogenicity Assessment Committee (CAC) and the Executive CAC). Also included under the Regulatory Guidance tab are links to Freedom of Information and the electronic document reading room. The link at http://www.fda.gov/cder/foi/index.htm explains how to get more detailed information through freedom of information requests if the web page and its links do not lead one to sufficient details.
At the CDER/FDA Guidance document web page, http://www.fda.gov/cder/guidance/index.htm , of particular interest are the International Conference on Harmonisation (ICH) and FDA Guidance documents. ICH Guidances are the product of agreements among the United States, the EU, and Japan. ICHM3 (R1) Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals discusses when in pharmaceutical development various nonclinical studies need to be conducted. The ICH S1 guidances discuss various aspects of carcinogenicity studies. The S2 guidances discuss genotoxicity. The S5 guidances discuss reproductive toxicity. Other ICH S series guidances discuss pharmaco/toxicokinetics, safety pharmacology, biotechnology-derived products, and immunotoxicity. The Q3 documents discuss when impurities need to be investigated and possible nonclinical studies needed.
On the Guidance document web page under Pharmacology/Toxicology http://www.fda.gov/cder/guidance/ index.htm#Pharmacology/Toxicology , CDER/FDA also has guidances on a variety of topics that include nonclinical issues: For additional links of interest to pharmacology see: http://www.fda.gov/nctr/index.html , which describes nonclinical research efforts of NCTR/ FDA, a number of which relate to issues or pharmaceuticals regulated by CDER or relate to methods that could be used by CDER. http://www.fda. gov/cder/genomics/default.htm describes initiatives in the area of "omics."
In addition to copies of approved labeling, http://www. accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm , gives information on genotoxicity, carcinogenicity, reproductive and developmental toxicity of drugs, and http://www. fda.gov/cder/drug/DrugSafety/DrugIndex.htm contains patient information for specific drugs. http://www.fda.gov/ cder/biologics/default.htm contains information on therapeutic biological products. http://www.fda.gov/ cder/Offices/ OTC/default.htm delves into issues of over-the-counter drugs.
The Medwatch program, whose purpose is to promote and facilitate voluntary reporting of serious adverse events and product problems with drugs by health care practitioners is described at http://www.fda.gov/ cder/handbook/ medwatch.htm . A special web site for Medwatch, outside the CDER web site, is at http://www.fda.gov/medwatch/ index.html . At this site, safety alert information is given, as well as instructions on how to report safety information.
From time to time specific safety issues arise, and information is provided on the CDER/FDA web page. http://www.fda.gov/cder/livertox on drug-induced liver toxicity is one such example.
Finally, since pharmacologist and toxicologist reviewers are always being sought, see http://www.fda.gov/ cder/career/default.htm for career opportunities.
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